Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.

Dutasteride does not impair mental function in elderly men with enlarged prostate.

Finasteride before TURP reduces blood loss and improves early postoperative quality of life.

The document concludes that PK/PD modeling is important for determining the safe and effective dosages of drugs.

Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.

Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.

Finasteride treats baldness but may cause lasting sexual side effects.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Early hair loss may indicate prostate issues.

5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.

Finasteride may cause breast enlargement, low testosterone a risk factor.

Finasteride's sexual side effects may be due to nocebo effect.

Finasteride and dutasteride are equally effective and safe for treating BPH.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

Finasteride increases hair count in middle-aged and elderly men without causing sexual dysfunction.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.

Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.

The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.

Finasteride and methadone don't increase advanced liver disease risk in HCV+ male veterans.